ChAd63-MVA-vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans

Overview

Journal Mol Ther

Publisher Cell Press

Specialties Molecular Biology
Pharmacology

Date 2012 Oct 24

PMID 23089736

Citations 135

Authors

Susanne H Sheehy

Christopher J A Duncan

Sean C Elias

Prateek Choudhary

Sumi Biswas

Fenella D Halstead

Katharine A Collins

Nick J Edwards

Alexander D Douglas

Nicholas A Anagnostou

Katie J Ewer

Tom Havelock

Tabitha Mahungu

Carly M Bliss

Kazutoyo Miura

Ian D Poulton

Patrick J Lillie

Richard D Antrobus

Eleanor Berrie

Sarah Moyle

Katherine Gantlett

Stefano Colloca

Riccardo Cortese

Carole A Long

Robert E Sinden

Sarah C Gilbert

Alison M Lawrie

Tom Doherty

Saul N Faust

Alfredo Nicosia

Adrian V S Hill

Simon J Draper

Affiliations

Soon will be listed here.

Abstract

The induction of cellular immunity, in conjunction with antibodies, may be essential for vaccines to protect against blood-stage infection with the human malaria parasite Plasmodium falciparum. We have shown that prime-boost delivery of P. falciparum blood-stage antigens by chimpanzee adenovirus 63 (ChAd63) followed by the attenuated orthopoxvirus MVA is safe and immunogenic in healthy adults. Here, we report on vaccine efficacy against controlled human malaria infection delivered by mosquito bites. The blood-stage malaria vaccines were administered alone, or together (MSP1+AMA1), or with a pre-erythrocytic malaria vaccine candidate (MSP1+ME-TRAP). In this first human use of coadministered ChAd63-MVA regimes, we demonstrate immune interference whereby responses against merozoite surface protein 1 (MSP1) are dominant over apical membrane antigen 1 (AMA1) and ME-TRAP. We also show that induction of strong cellular immunity against MSP1 and AMA1 is safe, but does not impact on parasite growth rates in the blood. In a subset of vaccinated volunteers, a delay in time to diagnosis was observed and sterilizing protection was observed in one volunteer coimmunized with MSP1+AMA1-results consistent with vaccine-induced pre-erythrocytic, rather than blood-stage, immunity. These data call into question the utility of T cell-inducing blood-stage malaria vaccines and suggest that the focus should remain on high-titer antibody induction against susceptible antigen targets.

Citing Articles

Controlled human malaria infection: overview and potential application in the evaluation of transmission-blocking interventions in malaria-endemic areas.

Kessy E, Olotu A Malar J. 2025; 24(1):33.

PMID: 39893367 PMC: 11786456. DOI: 10.1186/s12936-025-05277-x.

Role of homologous recombination/recombineering on human adenovirus genome engineering: Not the only but the most competent solution.

Dawson L, Alshawabkeh M, Schroer K, Arakrak F, Ehrhardt A, Zhang W Eng Microbiol. 2024; 4(1):100140.

PMID: 39628785 PMC: 11611009. DOI: 10.1016/j.engmic.2024.100140.

Full-length MSP1 is a major target of protective immunity after controlled human malaria infection.

Rosenkranz M, Nkumama I, Ogwang R, Kraker S, Blickling M, Mwai K Life Sci Alliance. 2024; 7(8).

PMID: 38803222 PMC: 11106525. DOI: 10.26508/lsa.202301910.

Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses.

DAlise A, Leoni G, Cotugno G, Siani L, Vitale R, Ruzza V Clin Cancer Res. 2024; 30(11):2412-2423.

PMID: 38506710 PMC: 11145154. DOI: 10.1158/1078-0432.CCR-23-3940.

PvDBPII elicits multiple antibody-mediated mechanisms that reduce growth in a Plasmodium vivax challenge trial.

Martinez F, White M, Guillotte-Blisnick M, Huon C, Boucharlat A, Agou F NPJ Vaccines. 2024; 9(1):10.

PMID: 38184681 PMC: 10771494. DOI: 10.1038/s41541-023-00796-7.

References

Pichyangkul S, Tongtawe P, Kum-Arb U, Yongvanitchit K, Gettayacamin M, Hollingdale M . Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys. Vaccine. 2009; 28(2):452-62. DOI: 10.1016/j.vaccine.2009.10.022. View

Riley E, Allen S, Wheeler J, Blackman M, Bennett S, TAKACS B . Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) of Plasmodium falciparum are associated with reduced malaria morbidity. Parasite Immunol. 1992; 14(3):321-37. DOI: 10.1111/j.1365-3024.1992.tb00471.x. View

Holder A . The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to malaria. Parasitology. 2009; 136(12):1445-56. DOI: 10.1017/S0031182009990515. View

Xu H, Hodder A, Yan H, Crewther P, Anders R, Good M . CD4+ T cells acting independently of antibody contribute to protective immunity to Plasmodium chabaudi infection after apical membrane antigen 1 immunization. J Immunol. 2000; 165(1):389-96. DOI: 10.4049/jimmunol.165.1.389. View

Saul A, Lawrence G, Smillie A, Rzepczyk C, Reed C, Taylor D . Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Vaccine. 1999; 17(23-24):3145-59. DOI: 10.1016/s0264-410x(99)00175-9. View

Bouharoun-Tayoun H, Attanath P, Sabchareon A, CHONGSUPHAJAISIDDHI T, Druilhe P . Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med. 1990; 172(6):1633-41. PMC: 2188756. DOI: 10.1084/jem.172.6.1633. View

Forbes E, Biswas S, Collins K, Gilbert S, Hill A, Draper S . Combining liver- and blood-stage malaria viral-vectored vaccines: investigating mechanisms of CD8+ T cell interference. J Immunol. 2011; 187(7):3738-50. PMC: 3284248. DOI: 10.4049/jimmunol.1003783. View

Douglas A, Williams A, Illingworth J, Kamuyu G, Biswas S, Goodman A . The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat Commun. 2011; 2:601. PMC: 3504505. DOI: 10.1038/ncomms1615. View

Walther M, Woodruff J, Edele F, Jeffries D, Tongren J, King E . Innate immune responses to human malaria: heterogeneous cytokine responses to blood-stage Plasmodium falciparum correlate with parasitological and clinical outcomes. J Immunol. 2006; 177(8):5736-45. DOI: 10.4049/jimmunol.177.8.5736. View

10.

Sheehy S, Duncan C, Elias S, Biswas S, Collins K, OHara G . Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One. 2012; 7(2):e31208. PMC: 3283618. DOI: 10.1371/journal.pone.0031208. View

11.

OHara G, Duncan C, Ewer K, Collins K, Elias S, Halstead F . Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis. 2012; 205(5):772-81. PMC: 3274376. DOI: 10.1093/infdis/jir850. View

12.

Bejon P, Andrews L, Andersen R, Dunachie S, Webster D, Walther M . Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J Infect Dis. 2005; 191(4):619-26. DOI: 10.1086/427243. View

13.

Hermsen C, Telgt D, Linders E, van de Locht L, Eling W, Mensink E . Detection of Plasmodium falciparum malaria parasites in vivo by real-time quantitative PCR. Mol Biochem Parasitol. 2001; 118(2):247-51. DOI: 10.1016/s0166-6851(01)00379-6. View

14.

Duncan C, Draper S . Controlled human blood stage malaria infection: current status and potential applications. Am J Trop Med Hyg. 2012; 86(4):561-5. PMC: 3403771. DOI: 10.4269/ajtmh.2012.11-0504. View

15.

Draper S, Moore A, Goodman A, Long C, Holder A, Gilbert S . Effective induction of high-titer antibodies by viral vector vaccines. Nat Med. 2008; 14(8):819-21. PMC: 4822545. DOI: 10.1038/nm.1850. View

16.

Andrews L, Andersen R, Webster D, Dunachie S, Walther R, Bejon P . Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials. Am J Trop Med Hyg. 2005; 73(1):191-8. View

17.

Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A . Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med. 2012; 4(115):115ra1. PMC: 3627207. DOI: 10.1126/scitranslmed.3003155. View

18.

Draper S, Goodman A, Biswas S, Forbes E, Moore A, Gilbert S . Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria. Cell Host Microbe. 2009; 5(1):95-105. PMC: 2663714. DOI: 10.1016/j.chom.2008.12.004. View

19.

Hermsen C, de Vlas S, van Gemert G, Telgt D, Verhage D, Sauerwein R . Testing vaccines in human experimental malaria: statistical analysis of parasitemia measured by a quantitative real-time polymerase chain reaction. Am J Trop Med Hyg. 2004; 71(2):196-201. View

20.

Pombo D, Lawrence G, Hirunpetcharat C, Rzepczyk C, Bryden M, Cloonan N . Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet. 2002; 360(9333):610-7. DOI: 10.1016/S0140-6736(02)09784-2. View